I. MODIFIED AGREEMENTS | |||
Biotech Co.* |
Pharma Co. |
Change from original |
Terms/Details (Details) |
Cytokinetics |
GlaxoSmithKline plc (UK) |
Amended agreement provides Cytokinetics an expanded role in development of SB-743921 |
Cytokinetics will lead and fund development in certain hematological cancers and is entitled to additional milestone payments; GSK has an option to take over responsibility in those indications (9/27) |
Epigenomics |
Roche Diagnostics |
They extended a deal covering the development of five cancer diagnostic tests |
The R&D part of the collaboration was extended at least six months with the option to expand the deal; terms were not disclosed (9/30) |
Imcor |
GE Healthcare (UK) |
They resolved disputed patent claims covering ultrasound contrast agents |
GE Healthcare will pay $1M to Imcor and $200,000 to Alliance in license fees; all parties granted the others nonexclusive, royalty-free cross-licenses with the right to sublicense their respective ultrasound contrast agents (9/22) |
MedImmune |
Abbott Laboratories |
They amended U.S. co-promotion agreement on Synagis, a product for treating respiratory syncytial virus |
MedImmune will take full responsibility for product sales in the U.S. after June 2006; Abbott is entitled to a portion of sales and potential milestone payments (8/31) |
Prima Biomed Ltd. (Australia; ASX:PRR) |
AstraZeneca plc (UK) |
They extended research deal on Fc receptor technology until June 30 |
The deal from October 2004 was made with Prima Biomed subsidiary Arthron Pty. Ltd.; AstraZeneca retains an option to license the technology (9/27) |
II. TERMINATED AGREEMENTS | |||
BioTie |
Sanofi-Aventis Group (France) |
Sanofi did not renew option agreement in deal to develop a oral heparin-like product |
BioTie plans to continue the recombinant heparin program with a new development partner (10/17) |
Flamel |
TAP Pharmaceutical Products Inc. |
TAP terminated a deal to use Flamel's Micropump technology in the delivery of lansoprazole |
The compound is the active ingredient in TAP's Prevacid; TAP intends to move forward with a different formulation (9/5) |
Praecis |
Schering AG (Germany) |
Schering exercised its right to terminate agreement covering Praecis' Plenaxis product |
Schering cited the product not having received marketing authorization in Germany with a requisite label by June 30 as reason for ending the deal (9/28) |
|
Notes: # The information in the chart does not cover agreements between biotech companies or agricultural agreements. * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; HSE = Helsinki Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets. | |||
